Westminster, CA – December 1, 2021 – BioLargo, Inc.
(OTCQB:BLGO), a developer of sustainable cleantech technologies and
full-service environmental engineering company, announced it has signed a manufacturer’s
representative agreement with the ICS
Group, a premier manufacturer’s representative company that has provided innovative
wastewater, energy management, and renewable energy technology solutions to municipal
and industrial clients, primarily in the Midwestern United States, since 2009. As
this is the first manufacturer’s representative for BioLargo’s innovative water
treatment technologies, this represents an important step toward building a
commercial network for their sale and distribution.
ICS Group has been tasked to sell BioLargo’s two proprietary
water treatment technologies, the Advanced Oxidation System (AOS)
energy-efficient wastewater disinfection, micropollutant removal, and water
reuse technology, and the Aqueous Electrostatic Concentrator (AEC) technology
for affordable, low-waste treatment of PFAS-contaminated water, as well as
other water and wastewater treatment equipment that BioLargo offers as an
authorized reseller of other manufacturers. The ICS Group will also sell
BioLargo’s PFAS Testing Program service, which offers fast and affordable
testing of clients’ PFAS-contaminated water for the purposes of treatment
system optimization, and CupriDyne Clean, the company’s patented odor and
volatile organic compound (VOC) control product.
Paul Nygaard, President of ICS Group, said, “We specialize
in innovative water and wastewater process technologies. We always strive to
bring cutting edge technologies to the market that help our clients achieve
challenging treatment objectives. BioLargo’s unique technology platforms
definitely bring that capability to our treatment solutions.”
“ICS Group has a reputation of outstanding customer service,
making them the perfect choice to be our first manufacturer’s representative
for our technologies. They’re also known for taking on new and innovative
technologies that address unmet needs in the water treatment marketplace,” said
Tonya Chandler, BioLargo’s Director of Strategic Marketing and Business
Development. “We intend to add more sales representatives soon and hope they
will be as great a fit as the ICS Group to our values.”
About BioLargo, Inc.
BioLargo, Inc. (OTCQB:BLGO) invents, develops, and
commercializes innovative platform technologies to solve challenging
environmental problems like PFAS contamination, advanced water and wastewater
treatment, industrial odor and VOC control, air quality control, and infection
control. With over 13 years of extensive R&D, BioLargo holds a wide array
of issued patents, maintains a robust pipeline of products, and provides
full-service environmental engineering. Our peer-reviewed scientific approach
allows us to invent or acquire novel technologies and develop them to maturity
through our operating subsidiaries. With a keen emphasis on collaborations with
academic, municipal, and commercial organizations and associations, BioLargo
has proven itself with over 80 awarded grants and numerous pilot projects. We
monetize through direct sales, recurring service contracts, licensing
agreements, strategic joint venture formation and/or the sale of the IP. See
our website at www.BioLargo.com.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include without limitation those about
BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19
pandemic; anticipated revenue; and plans for future operations. These
statements involve risks and uncertainties, and actual results may differ
materially from any future results expressed or implied by the forward-looking
statements. Risks and uncertainties include without limitation: the effect of
the COVID-19 pandemic on the Company’s business, results of operations,
financial condition, and stock price; the effect of regional economic
conditions on the Company’s business, including effects on purchasing decisions
by consumers and businesses; the ability of the Company to compete in markets
that are highly competitive and subject to rapid technological change; the
ability of the Company to manage frequent introductions and transitions of
products and services, including delivering to the marketplace, and stimulating
customer demand for, new products, services, and technological innovations on a
timely basis; the dependency of the Company on the performance of distributors
of the Company’s products. More information on these risks and other potential
factors that could affect the Company’s business and financial results is
included in the Company’s filings with the SEC, including in the “Risk Factors”
and “Management’s Discussion and Analysis of Financial Condition and Results of
Operations” sections of the Company’s most recently filed periodic reports on
Form 10-K and Form 10-Q and subsequent filings. The Company assumes no
obligation to update any forward-looking statements or information, which speak
as of their respective dates.
No comments:
Post a Comment